LS
ALXN

Livforsakringsbolaget Skandia’s Alexion Pharmaceuticals ALXN Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,772
Closed -$2.16M – 661
2021
Q2 		$2.16M Buy
11,772
+1,200
+11% +$206K 0.13% 152
2021
Q1 		$1.62M Hold
10,572
– – 0.11% 169
2020
Q4 		$1.65M Buy
10,572
+1,700
+19% +$218K 0.14% 138
2020
Q3 		$1.01M Buy
8,872
+6,500
+274% +$701K 0.11% 167
2020
Q2 		$266K Hold
2,372
– – 0.03% 329
2020
Q1 		$213K Buy
2,372
+800
+51% +$78.5K 0.03% 330
2019
Q4 		$170K Sell
1,572
-1,000
-39% -$107K 0.02% 376
2019
Q3 		$252K Hold
2,572
– – 0.03% 363
2019
Q2 		$337K Buy
2,572
+600
+30% +$77.3K 0.04% 293
2019
Q1 		$267K Hold
1,972
– – 0.04% 302
2018
Q4 		$192K Hold
1,972
– – 0.03% 327
2018
Q3 		$274K Sell
1,972
-1,400
-42% -$176K 0.03% 334
2018
Q2 		$419K Hold
3,372
– – 0.04% 341
2018
Q1 		$376K Hold
3,372
– – 0.04% 352
2017
Q4 		$403K Sell
3,372
-900
-21% -$110K 0.04% 342
2017
Q3 		$599K Hold
4,272
– – 0.05% 305
2017
Q2 		$520K Hold
4,272
– – 0.05% 328
2017
Q1 		$518K Sell
4,272
-10,900
-72% -$1.41M 0.05% 324
2016
Q4 		$1.86K Buy
15,172
+8,472
+126% +$1.04M 0.09% 230
2016
Q3 		$729K Sell
6,700
-13,172
-66% -$1.7M 0.04% 526
2016
Q2 		$2.32M Hold
19,872
– – 0.1% 233
2016
Q1 		$2.77M Hold
19,872
– – 0.13% 174
2015
Q4 		$3.79M Sell
19,872
-200
-1% -$34.9K 0.18% 125
2015
Q3 		$3.14M Buy
20,072
+1,700
+9% +$310K 0.16% 123
2015
Q2 		$3.32M Hold
18,372
– – 0.16% 133
2015
Q1 		$3.18M Sell
18,372
-4,500
-20% -$815K 0.16% 135
2014
Q4 		$4.23M Sell
22,872
-5,900
-21% -$1.09M 0.2% 114
2014
Q3 		$4.77M Hold
28,772
– – 0.18% 131
2014
Q2 		$4.5M Hold
28,772
– – 0.16% 148
2014
Q1 		$4.38M Buy
+28,772
New +$4.57M 0.16% 144

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Livforsakringsbolaget Skandia's ALXN Position: Q3 2021 in Review

Livforsakringsbolaget Skandia sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11,772 shares — an estimated $2.16M sold.

Livforsakringsbolaget Skandia first reported a position in ALXN in Q1 2014 and held it in 30 quarters. The position peaked at $4.77M in Q3 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Livforsakringsbolaget Skandia reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Livforsakringsbolaget Skandia sold 11,772 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.16M.
  • Livforsakringsbolaget Skandia first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 30 quarters.
  • Livforsakringsbolaget Skandia's Alexion Pharmaceuticals position peaked at $4.77M in Q3 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Livforsakringsbolaget Skandia's 13F filing for Q3 2021, filed 28 Oct 2021.